Literature DB >> 33361305

Interplay among Different Fosfomycin Resistance Mechanisms in Klebsiella pneumoniae.

J M Rodríguez-Martínez1,2,3, F Docobo-Pérez4,2,3, M Ortiz-Padilla5,1,2,3, I Portillo-Calderón5,2,3, B de Gregorio-Iaria5, J Blázquez3,6, J Rodríguez-Baño5,2,3,7, A Pascual5,1,2,3.   

Abstract

The objectives of this study were to characterize the role of the uhpT, glpT, and fosA genes in fosfomycin resistance in Klebsiella pneumoniae and evaluate the use of sodium phosphonoformate (PPF) in combination with fosfomycin. Seven clinical isolates of K. pneumoniae and the reference strain (ATCC 700721) were used, and their genomes were sequenced. ΔuhpT, ΔglpT, and ΔfosA mutants were constructed from two isolates and K. pneumoniae ATCC 700721. Fosfomycin susceptibility testing was done by the gradient strip method. Synergy between fosfomycin and PPF was studied by checkerboard assay and analyzed using SynergyFinder. Spontaneous fosfomycin mutant frequencies at 64 and 512 mg/liter, in vitro activity using growth curves with fosfomycin gradient concentrations (0 to 256mg/liter), and time-kill assays at 64 and 307 mg/liter were evaluated with and without PPF (0.623 mM). The MICs of fosfomycin against the clinical isolates ranged from 16 to ≥1,024 mg/liter. The addition of 0.623 mM PPF reduced fosfomycin MIC between 2- and 8-fold. Deletion of fosA led to a 32-fold decrease. Synergistic activities were observed with the combination of fosfomycin and PPF (most synergistic area at 0.623 mM). The lowest fosfomycin-resistant mutant frequencies were found in ΔfosA mutants, with decreases in frequency from 1.69 × 10-1 to 1.60 × 10-5 for 64 mg/liter of fosfomycin. In the final growth monitoring and time-kill assays, fosfomycin showed a bactericidal effect only with the deletion of fosA and not with the addition of PPF. We conclude that fosA gene inactivation leads to a decrease in fosfomycin resistance in K. pneumoniae The pharmacological approach using PPF did not achieve enough activity, and the effect decreased with the presence of fosfomycin-resistant mutations.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Klebsiella pneumoniae; antimicrobial resistance; fosfomycin

Mesh:

Substances:

Year:  2021        PMID: 33361305      PMCID: PMC8092493          DOI: 10.1128/AAC.01911-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant Escherichia coli Harboring Extended-Spectrum β-Lactamases.

Authors:  Jun-Seob Kim; Da-Hyeong Cho; Myeongseo Park; Woo-Jae Chung; Dongwoo Shin; Kwan Soo Ko; Dae-Hyuk Kweon
Journal:  J Microbiol Biotechnol       Date:  2016-02       Impact factor: 2.351

Review 2.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

3.  Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens.

Authors:  Adam D Tomich; Erik H Klontz; Daniel Deredge; John P Barnard; Christi L McElheny; Megan L Eshbach; Ora A Weisz; Patrick Wintrode; Yohei Doi; Eric J Sundberg; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

4.  Molecular insights into fosfomycin resistance in Escherichia coli.

Authors:  M Ballestero-Téllez; F Docobo-Pérez; I Portillo-Calderón; J M Rodríguez-Martínez; L Racero; M S Ramos-Guelfo; J Blázquez; J Rodríguez-Baño; A Pascual
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

5.  Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli.

Authors:  Inés Portillo-Calderón; Miriam Ortiz-Padilla; Jose Manuel Rodríguez-Martínez; Belen de Gregorio-Iaria; Jesús Blázquez; Jesús Rodríguez-Baño; Alvaro Pascual; Fernando Docobo-Pérez
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

6.  Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.

Authors:  F Docobo-Pérez; G L Drusano; A Johnson; J Goodwin; S Whalley; V Ramos-Martín; M Ballestero-Tellez; J M Rodriguez-Martinez; M C Conejo; M van Guilder; J Rodríguez-Baño; A Pascual; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 7.  A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport.

Authors:  M D Marger; M H Saier
Journal:  Trends Biochem Sci       Date:  1993-01       Impact factor: 13.807

8.  Capsule deletion via a λ-Red knockout system perturbs biofilm formation and fimbriae expression in Klebsiella pneumoniae MGH 78578.

Authors:  Tzu-Wen Huang; Irene Lam; Hwan-You Chang; Shih-Feng Tsai; Bernhard O Palsson; Pep Charusanti
Journal:  BMC Res Notes       Date:  2014-01-08

9.  The RAST Server: rapid annotations using subsystems technology.

Authors:  Ramy K Aziz; Daniela Bartels; Aaron A Best; Matthew DeJongh; Terrence Disz; Robert A Edwards; Kevin Formsma; Svetlana Gerdes; Elizabeth M Glass; Michael Kubal; Folker Meyer; Gary J Olsen; Robert Olson; Andrei L Osterman; Ross A Overbeek; Leslie K McNeil; Daniel Paarmann; Tobias Paczian; Bruce Parrello; Gordon D Pusch; Claudia Reich; Rick Stevens; Olga Vassieva; Veronika Vonstein; Andreas Wilke; Olga Zagnitko
Journal:  BMC Genomics       Date:  2008-02-08       Impact factor: 3.969

10.  Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.

Authors:  Bhagwan Yadav; Krister Wennerberg; Tero Aittokallio; Jing Tang
Journal:  Comput Struct Biotechnol J       Date:  2015-09-25       Impact factor: 7.271

View more
  1 in total

1.  Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.

Authors:  Iain J Abbott; Elke van Gorp; Kelly L Wyres; Steven C Wallis; Jason A Roberts; Joseph Meletiadis; Anton Y Peleg
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.758

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.